Powering Autonomy: The Tesla-Samsung Chip Alliance
Samsung's $16.5 billion deal to supply Tesla with AI chips marks a major strategic alliance in the semiconductor and automotive sectors. This theme focuses on the ripple effects, highlighting companies in the automotive AI and chip manufacturing ecosystem poised to benefit from accelerated innovation and investment.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Samsung's $16.5 billion deal to supply Tesla with AI chips represents a major shift in the automotive technology landscape. This strategic alliance signals an acceleration in the race for vehicle autonomy and highlights how automakers are securing their semiconductor supply chains. The partnership creates ripple effects across the entire automotive AI and chip manufacturing ecosystem, presenting opportunities for companies positioned to benefit from this technological transformation.
What You Need to Know
This group focuses on companies across the automotive technology value chain, from semiconductor manufacturers and equipment providers to software developers and sensor technology specialists. The theme captures the broader ecosystem that supports autonomous driving systems, recognizing that major partnerships like Tesla-Samsung often catalyze growth and innovation throughout related industries. These stocks represent exposure to the long-term shift towards vehicle autonomy.
Why These Stocks
These companies were handpicked by professional analysts based on their strategic positioning within the automotive AI and semiconductor ecosystem. Each stock represents a different aspect of the value chain that could benefit from increased investment and innovation driven by major partnerships like the Tesla-Samsung deal. The selection focuses on companies with the potential to capitalize on the accelerated push towards autonomous driving technology.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+102.15%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 102.15% over the next year.
Stocks Rated Buy by Analysts
12 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Game-Changing Partnership
The $16.5 billion Tesla-Samsung deal is reshaping the automotive AI landscape. This massive investment signals a new era of strategic alliances that could accelerate innovation across the entire autonomous driving ecosystem.
Supply Chain Revolution
Major automakers are securing their semiconductor supply chains through long-term partnerships. This trend creates opportunities for companies positioned throughout the automotive technology value chain to benefit from increased demand and investment.
Autonomy Race Intensifies
As the push for vehicle autonomy accelerates, companies developing AI chips, sensors, and supporting technologies are becoming increasingly valuable. This group captures key players positioned to capitalize on the autonomous driving revolution.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.